The 2022 AHA/ACC/HFSA guideline for the management of HF recommended the use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and stage A or stage B of HF [4]. This evidence concerns the gene SLC5A2 and diabetes mellitus.